She added: "What I see the marketing of these drugs doing is that it minimises and dismisses the root of weight gain, and instead focuses on simply appetite reduction
Combining genetic predisposition data with current biomarkersinsulin levels, metabolic markers, and weight trajectory on medicationcan support a more informed conversation with your provider about whether discontinuation aligns with your metabolic health profile or whether continued therapy better addresses your long-term wellness goals
Currently, my research focuses on human metabolism, regulation of appetite and food intake, and the pathophysiology of obesity and related disorders, including type 2 diabetes and non-alcoholic fatty liver disease
What This Means for Metabolic Medicine I think the bigger story here isn't about any single drug
The proposed explanation is that GHRH drives the somatotroph directly while the secretagogue additionally opposes somatostatins inhibitory tone [12]
Eligibility is a clinical judgment built from body mass index thresholds described in regulatory labeling, the presence or absence of weight-related health conditions, a screen for contraindications, and an assessment of whether medication fits a patients broader health picture